Revolution Medicines (RVMD) Intangibles (2019 - 2026)

Revolution Medicines has reported Intangibles for 8 years, with the latest figure at $55.8 million in Q1 2026.

• For the quarter ending Q1 2026, Intangibles fell 1.07% year-over-year to $55.8 million; the trailing twelve-month figure through Mar 2026 stood at $55.8 million (down 1.07% YoY), and the FY2025 full-year result was $63.3 million, up 11.66% from the prior year.
• Intangibles for Q1 2026 stood at $55.8 million, down from $63.3 million in the prior quarter.
• The five-year high for Intangibles was $63.3 million in Q2 2022, with the low at $69000.0 in Q3 2025.
• Average Intangibles over 5 years is $55.4 million, with a median of $56.4 million recorded in 2025.
• Year-over-year, Intangibles advanced 13.41% in 2022 and sank 99.89% in 2025.
• Tracing RVMD's Intangibles over 5 years: stood at $55.8 million in 2022, then advanced by 13.41% to $63.3 million in 2023, then declined by 10.45% to $56.7 million in 2024, then rose by 11.66% to $63.3 million in 2025, then retreated by 11.82% to $55.8 million in 2026.
• The last three Intangibles figures came in at $55.8 million (Q1 2026), $63.3 million (Q4 2025), and $69000.0 (Q3 2025), per Business Quant data.

Peer Comparison